Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1651 to 1665 of 2042 results for guidelines

  1. The Vest for delivering high-frequency chest wall oscillation in people with complex neurological needs (MIB159)

    NICE has developed a medtech innovation briefing (MIB) on The Vest for delivering high-frequency chest wall oscillation in people with complex neurological needs .

    Medtech innovation briefing
    Published
    14 September 2018

  2. Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (TA725)

    Evidence-based recommendations on abemaciclib (Verzenios) with fulvestrant for hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy in adults.

    Technology appraisal guidance
    Published
    15 September 2021
    View recommendations

    Sections for TA725

  3. Digitally enabled therapies for adults with anxiety disorders: early value assessment (HTE9)

    Early value assessment (EVA) guidance on digitally enabled therapies for adults with anxiety disorders....

    Health technology evaluation
    Last updated
    14 December 2023
    View recommendations

    Sections for HTE9

  4. NICE indicator process guide (PMG44)

    This guide describes the process NICE uses to develop indicators from NICE quality standards, NICE guidance and NICE accredited sources

  5. Spiral Flow peripheral vascular graft for treating peripheral arterial disease (MIB34)

    NICE has developed a medtech innovation briefing (MIB) on the Spiral Flow peripheral vascular graft for treating peripheral arterial disease

    Medtech innovation briefing
    Published
    21 July 2015

  6. Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma (TA857)

    Evidence-based recommendations on nivolumab (Opdivo) with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma in adults.

    Technology appraisal guidance
    Published
    11 January 2023
    View recommendations

    Sections for TA857

  7. Taxanes for the treatment of breast cancer (TA30)

    This guidance has been replaced by NICE guideline CG81.

    Technology appraisal guidance
    Published
    26 September 2001

  8. The clinical effectiveness and cost effectiveness of sibutramine for obesity (TA31)

    This guidance has been replaced by NICE guideline CG43. 

    Technology appraisal guidance
    Published
    28 October 2001

  9. Guidance on the use of gemcitabine for the treatment of pancreatic cancer (TA25)

    This guidance has been replaced by NICE guideline NG85.

    Technology appraisal guidance
    Published
    8 May 2001

  10. Orlistat for the treatment of obesity in adults (TA22)

    This guidance has been replaced by NICE guideline CG43.

    Technology appraisal guidance
    Published
    27 March 2001

  11. Wound care - debriding agents (TA24)

    This guidance has been replaced by NICE guideline CG74.

    Technology appraisal guidance
    Published
    27 April 2001

  12. Dyspepsia: Management of dyspepsia in adults in primary care (CG17)

    This guidance has been updated and replaced by NICE guideline CG184.

    Clinical guideline
    Published
    25 August 2004

  13. Schizophrenia (CG1)

    This guidance has been updated and replaced by NICE guideline CG82.

    Clinical guideline
    Published
    1 December 2002

  14. Type 2 diabetes foot problems: Prevention and management of foot problems (CG10)

    This guidance has been updated and replaced by NICE guideline NG19.

    Clinical guideline
    Published
    28 January 2004

  15. Infection control: prevention of healthcare-associated infection in primary and community care (CG2)

    This guidance has been updated and replaced by NICE guideline CG139.    

    Clinical guideline
    Published
    25 June 2003